- Home
- NPCE vs LXRX Comparison
NPCE vs LXRX Comparison
Compare NPCE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | LXRX |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.3M | 447.0M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NPCE | LXRX |
|---|---|---|
| Price | $17.32 | $1.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $18.00 | $3.23 |
| AVG Volume (30 Days) | 224.5K | ★ 1.7M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $94,864,000.00 | $70,864,000.00 |
| Revenue This Year | $24.82 | $56.61 |
| Revenue Next Year | $0.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.08 | ★ 1255.21 |
| 52 Week Low | $7.56 | $0.28 |
| 52 Week High | $18.98 | $1.66 |
Technical Indicators
Market Signals| Indicator | NPCE | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 42.39 |
| Support Level | $15.03 | $1.12 |
| Resistance Level | $16.33 | $1.23 |
| Average True Range (ATR) | 0.69 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 89.43 | 31.71 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.